← All trials
NCT04566276
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- Mar 31, 2021
- Completion date
- Jun 30, 2021
- First posted
- Sep 28, 2020
- Last posted
- Oct 6, 2020
- Enrollment
- 96
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chulalongkorn UniversityLead sponsor
- Chulalongkorn UniversityStudy director
- Government of ThailandCollaborator
- Chulalongkorn UniversityOfficial
- Mahidol UniversityCollaborator
- Chulalongkorn UniversityCollaborator
- Chulalongkorn UniversityCollaborator
- Chulalongkorn UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.